May 17, 2020

A breath test for diabetes, is it possible?

Oxoford Medical Diagnostics
breath test for diabetes
3 min
A breath test for diabetes could soon be reality
It is estimated that by 2030, over 300 million people worldwide will have diabetes. For some sufferers diabetes can have a huge effect on their day-to...

It is estimated that by 2030, over 300 million people worldwide will have diabetes. For some sufferers diabetes can have a huge effect on their day-to-lives, having to endure daily blood tests to monitor their condition. This can be inconvenient, traumatic and time consuming.

Oxford Medical Diagnostics (OMD) is a company with a speciality in the field of breath and gas analysis and it is currently developing new techniques to analyse human breath for the screening, diagnosis and monitoring of Type 1 and Type 2 diabetes.

So far, the company has raised almost £2 million in private investment to fund its research of these breath analysis devices. Healthcare Global caught up with David Taylor, a Technical Director at OMD to find out more about this latest healthcare innovation.

Exactly how does the breath screening of diabetes work?

One key symptom of diabetes is the uncontrolled burning of fat, owing to the inhibited use of blood glucose as a source of energy. This breakdown of fat leads to the enhanced production of one of the most abundant breath biomarkers – acetone –which many clinicians have highlighted as the ideal biomarker for the non-invasive screening, diagnosis and monitoring of diabetes. However, the amount of acetone found in the breath is very small; in general just a few parts per million, which makes the accurate detection of acetones particularly challenging.

OMD is developing two novel approaches to the quantitative detection of breath acetone: Cavity Enhanced Absorption Spectroscopy (CEAS) for a screening and diagnostic device and Plasma Emission Spectroscopy (PES) for a handheld monitoring device. Since breath contains up to 1,000 other biomarkers, the specificity of these techniques means that they serve as invaluable tools in the breath analysis market.

How will this test help people to manage their diabetes and improve their day-to-day lives?

For a diabetic, the daily drawing of blood currently required to monitor diabetes can be a disruptive and unpleasant routine. As a result, many diabetics don’t monitor themselves the four-seven times a day that clinicians recommend. A completely non-invasive breath test will be priceless in this respect, being totally painless and requiring minimal interaction from the user. It is hoped that diabetics will therefore feel inclined to monitor their condition more closely. This is particularly true of young sufferers, for whom daily blood tests are perhaps most traumatic. The particular device being developed for this purpose will be based on PES technology.

How is the development of the devices going? How far along is it?

The screening device based on CEAS technology is nearing the stage of prototype development. It is envisaged a product will be on the market within a year to 18 months from now. The daily monitoring device is less well developed as the PES technology it is based upon is still relatively new when compared with CEAS. That said, OMD aims to have a prototype developed by January 2013 and a product on the market another year or so after that.

What is the likelihood of the device eventually being available on a global scale?

Diabetes is a chronic condition that affects people all over the world. Recent reports from the World Health Organisation suggest that in the year 2000, 171 million people were said to be diabetic and this number if expected to double by 2030. Clearly, non-invasive screening and daily monitoring breath tests will become increasingly more important on a global scale. The company hopes to meet this need effectively with its products.

Our magazine is now available on the iPad. Click here to download it.

Share article

Jun 11, 2021

How UiPath robots are helping with the NHS backlog

6 min
UiPath software robots are helping clinicians at Dublin's Mater Hospital save valuable time

The COVID-19 pandemic has caused many hospitals to have logistical nightmares, as backlogs of surgeries built up as a result of cancellations. The BMJ has estimated it will take the UK's National Health Service (NHS) a year and a half to recover

However software robots can help, by automating computer-based processes such as replenishing inventory, managing patient bookings, and digitising patient files. Mark O’Connor, Public Sector Director for Ireland at UiPath, tells us how they deployed robots at Mater Hospital in Dublin, saving clinicians valuable time. 

When Did Mater Hospital implement the software robots - was it specifically to address the challenges of the pandemic? 
The need for automation at Mater Hospital pre-existed the pandemic but it was the onset of COVID-19 that got the team to turn to the technology and start introducing software robots into the workflow of doctors and nurses. 

The pandemic placed an increased administrative strain on the Infection Prevention and Control (IPC) department at Mater Hospital in Dublin. To combat the problem and ensure that nurses could spend more time with their patients and less time on admin, the IPC deployed its first software robots in March 2020. 

The IPC at Mater plans to continue using robots to manage data around drug resistant microbes such as MRSA once the COVID-19 crisis subsides. 

What tasks do they perform? 
In the IPC at Mater Hospital, software robots have taken the task of reporting COVID-19 test results. Pre-automation, the process created during the 2003 SARS outbreak required a clinician to log into the laboratory system, extract a disease code and then manually enter the results into a data platform. This was hugely time consuming, taking up to three hours of a nurse’s day. 

UiPath software robots are now responsible for this task. They process the data in a fraction of the time, distributing patient results in minutes and consequently freeing up to 18 hours of each IPC nurse’s time each week, and up to 936 hours over the course of a year. As a result, the healthcare professionals can spend more time caring for their patients and less time on repetitive tasks and admin work. 

Is there any possibility of error with software robots, compared to humans? 
By nature, humans are prone to make mistakes, especially when working under pressure, under strict deadlines and while handling a large volume of data while performing repetitive tasks.  

Once taught the process, software robots, on the other hand, will follow the same steps every time without the risk of the inevitable human error. Simply speaking, robots can perform data-intensive tasks more quickly and accurately than humans can. 

Which members of staff benefit the most, and what can they do with the time saved? 
In the case of Mater Hospital, the IPC unit has adopted a robot for every nurse approach. This means that every nurse in the department has access to a robot to help reduce the burden of their admin work. Rather than spending time entering test results, they can focus on the work that requires their human ingenuity, empathy and skill – taking care of their patients. 

In other sectors, the story is no different. Every job will have some repetitive nature to it. Whether that be a finance department processing thousands of invoices a day or simply having to send one daily email. If a task is repetitive and data-intensive, the chances are that a software robot can help. Just like with the nurses in the IPC, these employees can then focus on handling exceptions and on work that requires decision making or creativity - the work that people enjoy doing. 

How can software robots most benefit healthcare providers both during a pandemic and beyond? 
When the COVID-19 outbreak hit, software robots were deployed to lessen the administrative strain healthcare professionals were facing and give them more time to care for an increased number of patients. With hospitals around the world at capacity, every moment with a patient counted. 

Now, the NHS and other healthcare providers face a huge backlog of routine surgeries and procedures following cancellations during the pandemic. In the UK alone, 5 million people are waiting for treatment and it’s estimated that this could cause 6,400 excess deaths by the end of next year if the problem isn’t rectified.

Many healthcare organisations have now acquired the skills needed to deploy automation, therefore it will be easier for them to build more robots to respond to the backlog going forwards. Software robots that had been processing registrations at COVID test sites, for example, could now be taught how to schedule procedures, process patient details or even manage procurement and recruitment to help streamline the processes associated with the backlog. The possibilities are vast. 

The technology, however, should not be considered a short-term, tactical and reactive solution that can be deployed in times of crisis. Automation has the power to solve systematic problems that healthcare providers face year-round. Hospital managers should consider the wider challenge of dealing with endless repetitive work that saps the energy of professionals and turns attention away from patient care and discuss how investing in a long-term automation project could help alleviate these issues. 

How widely adopted is this technology in healthcare at the moment?
Automation was being used in healthcare around the world before the pandemic, but the COVID-19 outbreak has certainly accelerated the trend.  

Automation’s reach is wide. From the NHS Shared Business Service in the UK to the Cleveland Clinic in the US and healthcare organisations in the likes of Norway, India and Canada, we see a huge range of healthcare providers deploying automation technology. 

Many healthcare providers, however, are still in the early stages of their journeys or are just discovering automation’s potential because of the pandemic. I expect to see the deployment of software robots in healthcare grow over the coming years as its benefits continue to be realised globally. 

How do you see this technology evolving in the future? 
If one thing is certain, it’s that the technology will continue to evolve and grow over time – and I believe there will come a point in time when all processes that can be automated, will be automated. This is known as the fully automated enterprise. 

By joining all automation projects into one enterprise-wide effort, the healthcare industry can tap into the full benefits of the technology. This will involve software robots becoming increasingly intelligent in order to reach and improve more processes. Integrating the capabilities of Artificial Intelligence and Machine Learning into automation, for example, will allow providers to reach non-rule-based processes too. 

We are already seeing steps towards this being taken by NHS Shared Business Service, for example. The organisation, which provides non-clinical services to around two-thirds of all NHS provider trusts and every clinical commissioning organisation in the UK, is working to create an entire eco-system of robots. It believes that no automation should be looked at in isolation, but rather the technology should stretch across departments and functions. As such, inefficiencies in the care pathway can be significantly reduced, saving healthcare providers a substantial amount of time and money. 

Share article